Backing for German company with 'compelling position in the ADC field'
Tubulis, a Munich, Germany-based biotech company in the antibody drug conjugate (ADC) space, has announced the successful closing of a 60 million euros ($63 million) series B financing round.
The lead investor in the round is Andera Partners, a major European private equity player which, via its life science practice, invests in innovative companies from the biotech and medtech space.
"This funding emphasizes that Tubulis is uniquely positioned to consolidate the findings of the last 20 years in the ADC field"There was also participation from new backers Evotec and Fund+ and all existing investors participated in the round, including Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds, Occident and Seventure Partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze